US-based contract research organisation (CRO) Medpace has completed its integration of Symbios Clinical, the specialist medical device CRO it acquired in March.
Symbios Clinical will now be known as Medpace Medical Device (MMD) and will continue to provide expertise in pre-market, post-approval and post-market/outcomes trials, Medpace said.
The Symbios management team remains in place, while MMD will continue to operate out of its existing offices in Minneapolis, US, but with “the added flexibility to consult and conduct device trials on a global basis as a member of the Medpace group of companies”, Medpace noted.
The new subsidiary can also provide access to Medpace’s therapeutic and executive-level expertise, integrated core laboratory and imaging services, and enhanced safety management offering, its parent added.
“This will further enhance MMD’s leadership position as a best-in-class CRO for the design and execution of medical device trials,” it said.
Through the integration of Symbios Clinical, “we believe we offer our customers something completely different and unique – true medical device expertise with a comprehensive and global service offering through one provider”, commented MMD general manager Ryan Wilson.
“This allows us to have tighter control over project timelines and [to] make the outsourcing experience more seamless for our customers.”
Symbios Clinical was founded by Wilson, its former chief executive officer, and managing partner Ethan Rooney in 2006.
The Symbios offering includes study design, site management, project management, monitoring and data management for device trials, with experience in multiple therapy areas including cardiovascular and metabolic diseases.
